Skip to main content

Multiple Myeloma

Multiple Myeloma, Conference Highlights ASCO

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Multiple Myeloma, Select Drug Profiles

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

FDA Approvals, Multiple Myeloma, Select Drug Profiles

FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma

FDA Approvals, Multiple Myeloma

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

Multiple Myeloma

Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma

Wayne Kuznar

Multiple Myeloma

CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma

Chase Doyle

Multiple Myeloma

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Phoebe Starr

Multiple Myeloma

Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma

Phoebe Starr

1
2
3
4

Page 1 of 6
Results 1 - 10 of 52